Duchenne UK is a lean, ambitious and highly focused charity with a clear vision: to fund and accelerate treatments and a cure for Duchenne muscular dystrophy, to help this generation of patients with DMD.
We believe strongly in partnerships, with academics and with biotechs. We fund all research, but we focus on translational projects, using our funds to help get promising therapies out of the laboratory and into the clinic where they can help patients. We believe in funding treatments that have a chance of making it to market, providing initial funding and then staying with them on that journey.
To understand our impact and strategy please take a look at our infographic: download or open here. And read on for more detailed information about the individual projects we have funded.
Apply for funding: If you would like to discuss an idea for a research project or make a proposal for us to consider funding, please contact us in the first instance by sending an e-mail to David Bull, Director of Research: [email protected].
Please note that Duchenne UK does not pay indirect costs, or costs associated with normal overheads, as part of our funding awards for research projects.
Duchenne UK is a member of AMRC.
Read our animal research policy here.
An exciting new gene-based therapy on the horizon Read more
Our new research project aims to discover if and why a fermented soy product called Haelan 951 may help those with DMD. Read more
Already existing drugs developed for other conditions could be helpful to those with DMD Read more
Duchenne UK is co-funding a study into the use of elastase inhibitors to treat the symptoms of DMD in partnership with Joining Jack and Charley's Fund. Read more
Solid Biosciences Gene Therapy Programme is currently in Phase I/II clinical trial for its investigational microdystrophin gene transfer for the treatment of Duchenne. Read more
Duchenne UK partners with Solid Biosciences, to investigate the possible benefits of statins in patients. Can simvastatin reduce muscle damage and enhanced muscle function? Read more
ReveraGen are running the clinical trial for Vamorolone which could offer a potential alternative to steroids Read more
Professor Dickson explores the technique of gene editing - cutting out the mutations that cause DMD Read more
Duchenne UK is pleased to announce its support of the development of the next generation of exon skipping drugs Read more
A clinical trial for an anti-inflammatory drug that could reduce the thickening of the muscles Read more
Summit Therapeutics found new biomarkers for DMD that could lead to new drugs related to SMT C1100 Read more
Discovering new follow-on compounds to increase utrophin levels more effectively than SMT C1100 Read more
Duplications in DNA can cause DMD. We are funding gene therapy research that aims to correct this. Read more
The project investigates how muscle fibre cells die in DMD and looks at ways to prevent this Read more
Stem cell and gene therapy combine in this new study which aims to repair muscle cells and tissue Read more
Professor Wood of Oxford University examines muscle tissue MicroRNAs to see if they are valid biomarkers for DMD. Read more
We are supporting work on CRISPR, a gene correcting tool that is showing promise as a treatment for DMD Read more
We fund a programme investigating if an exisiting compound can benefit DMD Read more